NCNA NuCana plc Sponsored ADR

NuCana Expands its Board of Directors with the Appointment of Bali Muralidhar

NuCana Expands its Board of Directors with the Appointment of Bali Muralidhar
EN
13/10/2020

Underlying

NCNANuCana plc Sponsored ADR

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on NuCana plc Sponsored ADR

 PRESS RELEASE
Free
NCNA NuCana plc Spon...

NuCana Compliant with All Nasdaq Continued Listing Criteria

NuCana Compliant with All Nasdaq Continued Listing Criteria Anticipated Cash Runway into 2029 EDINBURGH, United Kingdom, Sept. 05, 2025 (GLOBE NEWSWIRE) -- NuCana plc (Nasdaq: NCNA) (“NuCana” or the “Company”) announced that it has received formal notification from The Nasdaq Stock Market on September 4, 2025 confirming that the Company is in compliance with all applicable Nasdaq continued listing criteria, including the $1.00 minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2). As such, the previously disclosed Nasdaq listing matter has been closed. “As a result of the ...

September 5, 2025 1 EN
 PRESS RELEASE
Free
NCNA NuCana plc Spon...

NuCana to Present Data on NUC-7738’s Synergy with PD-1 Inhibitors at t...

NuCana to Present Data on NUC-7738’s Synergy with PD-1 Inhibitors at the ESMO Congress 2025 EDINBURGH, United Kingdom, Sept. 03, 2025 (GLOBE NEWSWIRE) -- NuCana plc (Nasdaq: NCNA) (“NuCana” or the “Company”) announced a presentation at the upcoming annual European Society for Medical Oncology (“ESMO”) congress being held October 17-21, 2025 in Berlin, Germany (the “ESMO Congress 2025”). The details of NuCana’s presentation at the meeting are as follows: Abstract Title: Patient Derived Organoids Reveal Synergy Between NUC-7738 and PD-1 Inhibition in Renal Cell Cancer Poster Number: 1530P...

September 3, 2025 1 EN
 PRESS RELEASE
Free
NCNA NuCana plc Spon...

NuCana Reports Second Quarter 2025 Financial Results and Provides Busi...

NuCana Reports Second Quarter 2025 Financial Results and Provides Business Update First Patients Dosed on Expansion Study of NUC-7738 in Combination with Pembrolizumab for Patients with PD-1 Inhibitor-Resistant Melanoma Initial Data from the Expansion Study of NUC-7738 Expected in Q4 2025 with Final Data in 2026 Additional Data from the Ongoing Phase 1b/2 Study of NUC-3373 in Combination with Pembrolizumab Remain on track for 2025 Strategic Execution of ATM Offering Extends Anticipated Cash Runway into 2029 EDINBURGH, United Kingdom, Aug. 20, 2025 (GLOBE NEWSW...

August 20, 2025 1 EN
 PRESS RELEASE
Free
NCNA NuCana plc Spon...

NuCana Announces ADS Ratio Change

NuCana Announces ADS Ratio Change EDINBURGH, United Kingdom, Aug. 01, 2025 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA) (“NuCana” or the “Company”) announces that it will implement the Company’s previously disclosed plans to change the ratio of its American Depository Shares (“ADSs”) to its ordinary shares from one (1) ADS, representing twenty-five (25) ordinary shares, to one (1) ADS representing five thousand (5,000) ordinary shares (the "ADS Ratio"). The change in the ADS Ratio is expected to become effective on August 11, 2025 (the "Effective Date").   For the Company's ADS holders,...

August 1, 2025 1 EN
 PRESS RELEASE
Free
NCNA NuCana plc Spon...

NuCana Cancels All Outstanding Series A Warrants Following Strategic A...

NuCana Cancels All Outstanding Series A Warrants Following Strategic ATM Execution EDINBURGH, United Kingdom, July 21, 2025 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA) (“NuCana” or the “Company”) announces it has successfully canceled all remaining Series A Warrants, issued in the registered direct offering on May 7, 2025, pursuant to its letter agreements with the holders of the Series A Warrants, having raised the full amount of capital required to complete the cancellation through its at-the-market offering. This follows the Company’s June 27, 2025 announcement of the agreements to ...

July 21, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch